If you typed Linear Clinical Research into a search box, you are probably building a CRO shortlist. This article uses only what Linear Clinical Research publishes (www.linear.org.au) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Linear Clinical Research publishes
Linear Clinical Research is a not-for-profit Phase I and first-in-patient organization in Perth, founded in 2010 by the Harry Perkins Institute. It runs centres in Nedlands, Joondalup and an Advanced Clinical Trial Centre for next-generation and cell therapies. It claims 4–6 week ethics approval, a 75,000+ volunteer database and 94.5% of cohorts dosed on time in FY24. Its public work is medicines, vaccines and CAR-T.
Linear Clinical Research vs bioaccess®
| Dimension | Linear Clinical Research | bioaccess® |
|---|---|---|
| Core focus | Drug Phase I + first-in-patient oncology / haematology | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you are a drug or cell-therapy sponsor that wants a fast Australian Phase I, Linear is a strong option.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Linear Clinical Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Linear Clinical Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the Linear Clinical Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply